All In Biotech

Drug Trial Radar · NCT05269459

Safety and Efficacy of Cannabidiol (CBD) for Symptoms of PTSD in Adults

Safety and Efficacy of Cannabidiol (CBD) for Symptoms of Post-Traumatic Stress Disorder (PTSD) in Adults Using Liquid StructureTM Formulation (NantheiaTM ATL5).

Last checked: Nov 20, 2026Latest source record: Sep 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 140 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

140

Planned (sponsor's estimate)

Start

Dec 1, 2022

Primary completion

Dec 2028

Study completion Apr 2029

Sponsor

Lead sponsor
University of NebraskaAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Ananda Scientific; University of Texas at Austin
First posted
Mar 8, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 21 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Post-traumatic stress disorder (PTSD) is a psychiatric disorder than may develop following a traumatic event including serious incidents, natural or human-caused disasters, violence, death of a loved one, receipt of traumatic news, or serious illness/hospitalization. While half of US adults experience trauma in their lifetime, most do not develop PTSD. However, those who do develop the disorder may have significant impairments and risk for functional dysfunction across multiple domains. While short term symptoms are the most common, some individuals develop chronic PTSD. These individuals may experience frightening and intrusive thoughts and memories of the event (flashbacks), have sleep disturbances, feel numb or detached, and be easily startled (hypervigilance). This trial is a double-blind placebo controlled study of cannabidiol (CBD) for symptoms of PTSD in adults using liquid structure Formulation (Nantheia ATL5). Participants complete three weeks of baseline data collection including assessments of activity and sleep. Intervention is Nantheia ATL5 or placebo. Dose is initiated at 400mg BID and maintained over 8 weeks. Standardized symptom profile measurements, clinician assessments, laboratory testing, and suicide screening is completed throughout.

Conditions

  • PTSD

Interventions

  • Cannabidiol Administered as Nantheia ATL5Drug

    Participants will take 4 gel capsules twice daily containing 100mg of Nantheia ATL5.

  • PlaceboDrug

    Participants will take 4 matching gel capsules twice daily containing no active drug.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Post-traumatic Stress Disorder Symptom RatingTime frame: Baseline and 8 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University of Nebraska Medical Center

    Omaha, Nebraska · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.